Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.
Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.
Status check updated to CJC-1295 DAC in Canada. Named in current Health Canada unauthorized peptide guidance.
Health Canada names CJC-1295 among examples of unauthorized injectable peptide drugs identified or seized in Canada. The Canadian records do not resolve a seller's DAC versus no-DAC format. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.
This record resolves a name to the US laboratory research catalog tracked by Peptide Local. It does not establish authorization, lawful supply, medical use, or availability in the selected destination.
A Canada-specific verification guide built around Health Canada’s peptide warning, the Drug Product Database, and provincial pharmacy licensing.
This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.
Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.
The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.
No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.
The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.
No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.
Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.
Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.
Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.